ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer…
Read moreNews & Views
Kevin Richardson Appointed as CEO, Telix Americas
News,
Telix announces that Kevin Richardson will commence in the role of CEO, Telix Americas, on 11 July…
Read more
Take a PSMA journey with Telix at EAU22
As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure…
Read more
Presentation to Jefferies Global Healthcare Conference
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies Global Healthcare Conference in New York City on Friday 10…
Read more
Telix at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June,…
Read more
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging…
Read more
Telix AGM 2022
Telix’s 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne,…
Read more
Telix at ANZSNM Annual Scientific Meeting 2022
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15…
Read more
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New…
Read more
Telix Further Strengthens European Distribution Network for Illuccix
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic…
Read more